RxDoctor Payments Data

Lauren Wong, MD

Rheumatology · Brooklyn, NYNPI 1760642912

Payments from drug & device makers

$1,085in general payments, 2019–2025

Across 25 payments — averaging $43.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Motiva USA, LLC$316
  • Integra Lifesciences Corporation$156
  • Johnson & Johnson$132
  • AbbVie$122
  • Amgen$110
  • GSK$98
  • plus $151 from 4 others

What the payments were for

  • Food & beverage$1,03295%
  • Education$535%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Motiva USA, LLC2$316
Integra Lifesciences Corporation1$156
Johnson & Johnson5$132
AbbVie1$122
Amgen5$110
GSK4$98
Novartis3$62
Sanofi-aventis U.S. LLC2$42
UCB, Inc.1$30
Biocon Biologics Inc1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,085 in reported general payments places this provider in the 40th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$167,305
Medicare patients
245
Services billed
4,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab74$599,759
StelaraUstekinumab17$492,485
RinvoqUpadacitinib62$434,678
Enbrel SureclickEtanercept29$203,060
EnbrelEtanercept22$153,663
OtezlaApremilast23$101,616
Cosentyx Sensoready (2 Pens)Secukinumab13$91,975
ProliaDenosumab31$52,127
Lidocaine115$21,231
Mycophenolate Mofetil54$13,100
Hydroxychloroquine Sulfate495$9,513
Leflunomide156$8,921
MethotrexateMethotrexate Sodium168$4,806
Diclofenac Epolamine13$4,011
Azathioprine21$3,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$132$492,48517 claims
AbbVieRinvoq$122$434,67862 claims
AmgenEnbrel, Otezla, Prolia$110$307,40576 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 541 rheumatology providers in New York.

Other rheumatology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →